Background: Ceftobiprole is approved in Europe for treatment of community-acquired pneumonia and non-ventilator-associated hospital-acquired pneumonia (HAP) in adults. Real-world data are limited. Methods: This multi-centre, observational, ambispective investigator-initiated study was undertaken in Italy from January 2018 to December 2019 in order to evaluate the use of ceftobiprole in a real-world setting. Results: Overall, 195 patients from 10 centres were evaluated (68% retrospectively). Male sex was prevalent (n=121, 62%). Median age was 67 [interquartile range (IQR) 53-75] years. Median Charlson Comorbidity Index score was 5 (IQR 3-7). The most common indication was pneumonia (151/195, 77%), especially HAP. Other uses were skin and soft tissue infections (5%), endocarditis (4%) and bone infections (4%). Ceftobiprole was usually an empiric choice (65%), in combination with other drugs (66%) and as second-line therapy (58%). A causative agent was found in 39% of cases. A diagnosis of sepsis was made in 59 cases (30%). Success in the clinically evaluable population (excluding 12 cases due to isolation of pathogens outside ceftobiprole's spectrum of activity) was obtained in 79% of cases, with all-cause mortality of 20%. On multi-level analysis, three predictors were positively associated with clinical success: male gender, pneumonia and detection of causal agent. Sepsis was a negative predictor. Nine factors were independently associated, favourably or unfavourably, with fatal outcome. Conclusions: Ceftobiprole is a safe and effective therapeutic choice, even in a real-world setting. More data are needed to establish its efficacy in patients with sepsis.

CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy / Gentile, Ivan; Buonomo, Antonio Riccardo; Corcione, Silvia; Paradiso, Laurenza; Giacobbe, Daniele Roberto; Bavaro, Davide Fiore; Tiseo, Giusy; Sordella, Francesca; Bartoletti, Michele; Palmiero, Giulia; Vozza, Antonietta; Vena, Antonio; Canta, Francesca; Moriello, Nicola Schiano; Congera, Paola; Karruli, Arta; Tascini, Carlo; Viale, Pierluigi; Bono, Valerio Del; Falcone, Marco; Carbonara, Sergio; Mikulska, Malgorzata Karolina; Bassetti, Matteo; Durante-Mangoni, Emanuele; De Rosa, Francesco Giuseppe; Maraolo, Alberto Enrico. - In: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. - ISSN 0924-8579. - 62:1(2023). [10.1016/j.ijantimicag.2023.106817]

CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy

Gentile, Ivan
;
Buonomo, Antonio Riccardo;Paradiso, Laurenza;Vozza, Antonietta;Moriello, Nicola Schiano;Congera, Paola;Maraolo, Alberto Enrico
Ultimo
Formal Analysis
2023

Abstract

Background: Ceftobiprole is approved in Europe for treatment of community-acquired pneumonia and non-ventilator-associated hospital-acquired pneumonia (HAP) in adults. Real-world data are limited. Methods: This multi-centre, observational, ambispective investigator-initiated study was undertaken in Italy from January 2018 to December 2019 in order to evaluate the use of ceftobiprole in a real-world setting. Results: Overall, 195 patients from 10 centres were evaluated (68% retrospectively). Male sex was prevalent (n=121, 62%). Median age was 67 [interquartile range (IQR) 53-75] years. Median Charlson Comorbidity Index score was 5 (IQR 3-7). The most common indication was pneumonia (151/195, 77%), especially HAP. Other uses were skin and soft tissue infections (5%), endocarditis (4%) and bone infections (4%). Ceftobiprole was usually an empiric choice (65%), in combination with other drugs (66%) and as second-line therapy (58%). A causative agent was found in 39% of cases. A diagnosis of sepsis was made in 59 cases (30%). Success in the clinically evaluable population (excluding 12 cases due to isolation of pathogens outside ceftobiprole's spectrum of activity) was obtained in 79% of cases, with all-cause mortality of 20%. On multi-level analysis, three predictors were positively associated with clinical success: male gender, pneumonia and detection of causal agent. Sepsis was a negative predictor. Nine factors were independently associated, favourably or unfavourably, with fatal outcome. Conclusions: Ceftobiprole is a safe and effective therapeutic choice, even in a real-world setting. More data are needed to establish its efficacy in patients with sepsis.
2023
CEFTO-CURE study: CEFTObiprole Clinical Use in Real-lifE – a multi-centre experience in Italy / Gentile, Ivan; Buonomo, Antonio Riccardo; Corcione, Silvia; Paradiso, Laurenza; Giacobbe, Daniele Roberto; Bavaro, Davide Fiore; Tiseo, Giusy; Sordella, Francesca; Bartoletti, Michele; Palmiero, Giulia; Vozza, Antonietta; Vena, Antonio; Canta, Francesca; Moriello, Nicola Schiano; Congera, Paola; Karruli, Arta; Tascini, Carlo; Viale, Pierluigi; Bono, Valerio Del; Falcone, Marco; Carbonara, Sergio; Mikulska, Malgorzata Karolina; Bassetti, Matteo; Durante-Mangoni, Emanuele; De Rosa, Francesco Giuseppe; Maraolo, Alberto Enrico. - In: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. - ISSN 0924-8579. - 62:1(2023). [10.1016/j.ijantimicag.2023.106817]
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0924857923000961-main.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 674.33 kB
Formato Adobe PDF
674.33 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/977128
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 12
social impact